Abstract 746: Activation of EGFR bypass signaling through TGFα overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells
Tetsuo Tani(Keio University), Kenzo Soejima(Keio University), Aoi Kuroda(Keio University), Yuichiro Hayashi(Nagoya University), Kota Ishioka(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Junko Hamamoto(Keio University), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Keiko Ohgino(Keio University)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101